Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Labcorp (LH)

Labcorp: Central Labs and International President Megan Bailey to resign effective Sept. 4

Neutral Impact 3 of 5 leadership Written later

Labcorp said executive Megan D. Bailey will resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., currently President of Early Development Research Laboratories and Chief Medical and Scientific Officer, will take a broader role effective September 1, 2026, overseeing Biopharma Laboratory Services along with the Early Development Research Laboratories and Central Laboratories businesses.

Key points

  • Megan D. Bailey notified the company of her resignation on August 11, 2026, effective September 4, 2026
  • Brian J. Caveney, M.D., takes on expanded role effective September 1, 2026
  • Caveney's new title: EVP and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer
  • The filing does not state a replacement for Bailey's former role or any financial terms

The filing

CompanyLabcorp (LH)
Form8-K, current report
Filed with the SECAug 14, 2026, 8:55 AM ET
Accession number0000920148-26-000182

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.